GS-5737 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	2

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01840735 (ClinicalTrials.gov)	May 2013	15/4/2013	Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF	A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of GS-5737 in Subjects With Cystic Fibrosis	Cystic Fibrosis	Drug: GS-5737;Drug: Placebo	Gilead Sciences	NULL	Completed	18 Years	N/A	Both	8	Phase 1	United States
2	NCT01793649 (ClinicalTrials.gov)	October 2012	14/2/2013	A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects	A Phase 1, Randomized, Double-Blind, Cross-Over, Vehicle-Controlled, Single-Dose Study To Characterize The Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) In Healthy Subjects	Cystic Fibrosis;Chronic Obstructive Pulmonary Disease	Drug: GS-5737	Gilead Sciences	NULL	Terminated	18 Years	45 Years	Both	7	Phase 1	United States